Generation Bio Co.(GBIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,631 of 2,856 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in GBIO
Events flagged as statistical outliers against GBIO's own multi-year baseline — not fixed dollar thresholds.
GBIO Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Generation Bio Co. (GBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GBIO at 23.1/100 on a 32-signal composite quality model, placing it at rank #2,631 of 2,856 stocks — the bottom half of the AI-ranked universe. GBIO scores in the top quartile across revenue growth (93.4). Areas of concern include institutional flow (1.3) and free cash flow (2.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2025), Generation Bio Co. reports quarterly revenue of $1.6M, net income of $-5.5M, free cash flow of $-52.7M. GBIO trades on the Nasdaq exchange and files with the SEC under CIK 1733294. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Generation Bio Co. directly from SEC EDGAR. Generation Bio Co.'s 13F Pro composite quality score has ranged between 13 and 29 since 2024, currently 23.1 — a stable long-term trajectory across 45 quarterly and live scoring snapshots.
Revenue
Q3 2025
$1.6M
Net Income
Q3 2025
$-5.5M
Free Cash Flow
Q3 2025
$-52.7M
ROIC
Q3 2025
-53.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+236.9% YoYNet Income
-4.0% YoYOperating Income
-2.8% YoYEPS (Diluted)
-1.0% YoYTotal Assets
-38.3% YoYOp. Cash Flow
-67.9% YoYFree Cash Flow
-51.2% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $19.9M +236.9% | $5.9M | $0.00 | $0.00 | — | — |
| Net Income | $-131.7M -4.0% | $-126.6M +7.3% | $-136.6M -14.7% | $-119.2M -48.0% | $-80.5M -31.3% | $-61.3M |
| Operating Income | $-142.4M -2.8% | $-138.6M +1.9% | $-141.2M -18.5% | $-119.1M -46.8% | $-81.1M -30.2% | $-62.3M |
| EPS (Diluted) | $-1.98 -1.0% | $-1.96 +16.6% | $-2.35 -10.8% | $-2.12 +28.1% | $-2.95 +77.2% | $-12.96 |
| Total Assets | $231.2M -38.3% | $374.8M -0.4% | $376.3M -21.1% | $476.8M +62.1% | $294.2M +598.0% | $42.1M |
| Operating Cash Flow | $-88.6M -67.9% | $-52.7M +48.5% | $-102.4M -11.6% | $-91.8M -30.9% | $-70.1M -73.9% | $-40.3M |
| Free Cash Flow | $-91.0M -51.2% | $-60.1M +45.9% | $-111.2M -13.8% | $-97.8M -29.2% | $-75.7M -25.4% | $-60.3M |
AI Insight: GBIO Financial Trends
Generation Bio's cash burn moderated sharply in Q3 2025, but revenue collapsed to $2M amid equity depletion.
• Net loss narrowed to $6M in Q3 2025 from $21M in Q2 2025, reflecting operational improvement despite minimal revenue.
• Equity eroded 75% from $203M (Q4 2023) to $51M (Q3 2025); no debt reported across all periods.
• Operating cash flow deteriorated to negative $53M in Q3 2025, the worst quarter on record despite narrowing losses.
⚠ Revenue collapsed from $9M (Q1 2025) to $1–2M in Q2–Q3 2025; early-stage programs may face clinical or commercialization headwinds.
⚠ At $51M equity and negative operating cash flow, runway appears constrained; near-term financing or milestone inflection critical.
AI Insight: GBIO Ratio Trends
Generation Bio remains deeply unprofitable with ROE deteriorating to -123.9% on TTM basis, though latest quarterly ROA and ROIC show modest sequential improvement.
• Q3 2025 ROA improved to -18.1% from -46.6% in Q2 2025; ROIC similarly rose to -53.1% from prior quarter.
• Operating margin worsened sharply to -190.4% in Q1 2025, indicating severe cash burn relative to any revenue generation.
• TTM ROE of -123.9% reflects cumulative shareholder value destruction; equity base eroding faster than losses narrowing.
⚠ Sequential Q2–Q3 2025 improvement in ROA/ROIC may signal pathway toward profitability or reflect one-time adjustments; sustainability unclear.
⚠ No OpMargin or NPM data for Q2 2025 and Q3 2025; inability to assess operating efficiency trends in most recent periods.
Get alerted when GBIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Generation Bio Co. including:
Top Institutional Holders of GBIO
HUNTINGTON NATIONAL BANK
$0.001 sh
| Fund | Value | Shares |
|---|---|---|
| HUNTINGTON NATIONAL BANK | $0.00 | 1 |
More Healthcare Companies
View all Healthcare →Put GBIO on your watchlist
Track score changes the day Generation Bio Co. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GBIO a good stock to buy?
13F Pro's AI-powered analysis of Generation Bio Co. (GBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GBIO are available on the GBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GBIO is classified as a small company.
Which hedge funds own GBIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Generation Bio Co.'s investment landscape.